Financial Performance - Fourth quarter 2024 revenue was $5.3 billion, representing a 2% year-over-year increase, driven by Advanced Visualization Solutions and Pharmaceutical Diagnostics[5] - Net income for the fourth quarter was $720 million, compared to $403 million in the prior year, resulting in a net income margin of 13.5%, up 580 basis points[5] - Diluted earnings per share (EPS) for the fourth quarter were $1.57, an increase of $0.69 from the prior year[5] - Full year 2024 total revenues reached $19.7 billion, a 1% increase year-over-year, with net income attributable to GE HealthCare at $2.0 billion[10] - Net income from continuing operations for 2024 was $2,050 million, compared to $1,618 million in 2023, reflecting an increase of 27%[21] - Organic revenue for the year ended December 31, 2024, was $19,737 million, a 1% increase from $19,552 million in 2023[29] - Adjusted EPS for 2025 is expected to be in the range of $4.61 to $4.75, reflecting a growth of 3% to 6% compared to 2024[12] - Adjusted net income for Q4 2024 reached $666 million, a 24% increase compared to $539 million in Q4 2023[38] - The effective tax rate for Q4 2024 was 11.5%, significantly lower than 31.7% in Q4 2023[45] - Adjusted earnings per share for Q4 2024 was $1.45, an increase of 22.88% from $1.18 in Q4 2023[42] Cash Flow and Investments - Cash, cash equivalents, and restricted cash at the end of 2024 totaled $2,893 million, up from $2,506 million in 2023, marking a 15% increase[22] - The company reported a Free cash flow of $1,955 million for 2024, down from $2,101 million in 2023[21] - Free cash flow for Q4 2024 was $811 million, down 15% from $956 million in Q4 2023[47] - The company invested $401 million in property, plant, and equipment and internal-use software during 2024, compared to $387 million in 2023[21] - Long-term borrowings decreased to $7,449 million in 2024 from $8,436 million in 2023, a reduction of 12%[19] Business Operations and Strategy - The company reported a total book-to-bill ratio of 1.09 times for the fourth quarter, with orders increasing 6% organically year-over-year[5] - GE HealthCare introduced approximately 40 innovations in 2024 and closed over 50 strategic enterprise deals globally[8] - The company plans to invest $138 million in its manufacturing facility in Cork, Ireland, to meet increasing demand for contrast media[11] - GE HealthCare will acquire the remaining 50% stake in Nihon Medi-Physics, enhancing its position in the radiopharmaceutical market in Japan[15] - The company anticipates continued growth in organic revenue and adjusted EBIT margin based on internal forecasts[48] - GE HealthCare's strategic focus includes improving demand for its products and managing healthcare costs effectively[53] Market and Industry Context - The company is focused on advancing personalized, connected, and compassionate care through innovative medical technology and AI-enabled solutions[54] - GE HealthCare is navigating risks related to global geopolitical instability, public health crises, and competitive market dynamics[53] - The company has been recognized as one of the 2025 Fortune World's Most Admired Companies[55] Research, Development, and Compliance - The company emphasizes the importance of maintaining successful research and development efforts for commercially viable products[53] - GE HealthCare is committed to compliance with various legal and regulatory requirements, including anti-corruption laws[53] - The company is focused on attracting and retaining key personnel to support its growth initiatives[53] Profitability Metrics - Adjusted EBIT for the year ended December 31, 2024, was $3,211 million, reflecting a 9% increase from $2,956 million in 2023[33] - Adjusted EBIT margin for 2024 was not specified, but the company emphasizes ongoing operations and underlying profitability factors[25] - The adjusted EBIT margin for Q4 2024 was 18.7%, an increase of 260 basis points from 16.1% in Q4 2023[33]

Core Viewpoint - GE HealthCare Technologies Inc. (GEHC) is expected to report mixed performance for Q4 2024, driven by strong U.S. demand and product innovation, but facing challenges from ongoing weakness in the Chinese market [3][5][18] Financial Performance - The Zacks Consensus Estimate for GEHC's Q4 revenues is $5.33 billion, indicating a year-over-year growth of 2.4% [12] - The estimated earnings per share (EPS) for Q4 is $1.26, reflecting an improvement of 6.8% from the previous year [12] Market Dynamics - GEHC experienced 1% organic revenue growth in Q3 2024, with expectations of steady performance in Q4 due to backlog execution and operational efficiencies [3][4] - The company’s strategic focus on multiyear enterprise agreements, particularly in imaging and service contracts, is anticipated to bolster revenue growth [4] Segment Performance - The Imaging segment is expected to remain a core revenue driver, although it faced a 1% organic revenue decline in Q3 due to sluggish demand in China [7] - Patient Care Solutions achieved 2% organic revenue growth in Q3, benefiting from backlog execution and increased fulfillment capacity [9] - The Pharmaceutical Diagnostics segment showed strong performance with 7% organic revenue growth in the last reported quarter, driven by increased procedure volumes [10][11] Innovation and Product Development - GEHC introduced new innovations in Q3, including a software tool for radiation dose measurement, which is expected to enhance clinical efficiency and patient safety [6] - The launch of Ocado, a newly FDA-approved PET tracer for coronary artery disease, is anticipated to drive long-term growth in the pharmaceutical diagnostics segment [10][15] Challenges and Outlook - Ongoing macroeconomic challenges, particularly in China, are expected to impact capital equipment sales and overall revenue growth [5][18] - Despite these challenges, GEHC's diversified global presence and strong U.S. performance provide a buffer against uncertainties [18]

GE HealthCare Technologies Inc. (GEHC) recently announced a $138 million investment to expand its manufacturing facility in Cork, Ireland. This initiative will boost the production of imaging contrast media, a critical component in diagnostic procedures, and strengthen GEHC's global supply chain to meet growing healthcare demands.The new state-of-the-art facility on the grounds of the existing site is likely to enable 25 million more patient doses per year of contrast media by the end of 2027, helping addre ...

GE HealthCare Technologies Inc. (GEHC) recently announced receiving FDA 510(k) clearance for its updated Voluson Expert Series ultrasound systems. This advanced portfolio, which includes the Voluson Expert 22, 20, and 18, sets a new benchmark in women’s healthcare by combining exceptional image quality, cutting-edge ultrasound technology, and ergonomic design to enhance workflow efficiency and deliver an unparalleled user experience.The Voluson Expert Series is equipped with artificial intelligence (AI)-pow ...

Back when General Electric ( GE ) was its own standalone conglomerate, I believed that there was significant upside potential through the firm splitting off its operating segments. That ultimately occurred, and the upside enjoyed by investors has been massive. One of theCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 5 ...

2025年1月31日， GE医疗 宣布投资 1.38亿 美元（约合10亿元人民币） ，以扩建其位于 爱尔兰科克郡 Carrigtohill 的造影剂制造工厂 。 随着全球造影剂 需求的激增，此项投资确保了供应链的稳定性和生产能力的提升。 新设施将采用先进的自动化系统，提高制造效率和灵活性。 # GE医疗其他造 影剂生产基地 GE医疗集团在全球运营多个造影剂生产基地，确保强大的供应链能力，满足不断增长的全球需求。 施工计划于2025年2月启动，预计 将创造超过250个建筑相关岗位 ，这也凸显了爱尔兰作为制药创新和制造中心的重要地位。 这项投资 加强了GE医疗在爱尔兰的长期业务及其与 IDA Ireland 的合作伙伴关系。 工厂将专注于 碘基造影剂 ，这对于提高医疗保健机构的诊断准确性至关重要，旨在满足全球对碘基造影剂日益增长的需求。 此次扩建将涉及在现有场地上建造一个3000平方米的新先进设施，这些产品用于 X 射线、CT 扫描和介入手术等医学成像程序，以增强器官、血管和组织的 可视化。 造影剂是一种可注射的诊断成像剂，在医学影像检查过程中起着至关重要的作用。 它能够增强器官、血管和组织的可视化效果，使医生能 ...

GE HealthCare Technologies Inc. (GEHC) and the University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging recently announced the launch of a Care Innovation Hub, a joint research collaboration.The collaboration aims to address meaningful clinical challenges in three key areas — accessibility to advanced medical imaging, non-invasive diagnosis and management of neurological and neurodegenerative disease and precision oncology.Likely Trend of GEHC Stock Following the NewsFollo ...

GE HealthCare Technologies, Inc. (GEHC) is well-poised for growth in the coming quarters, courtesy of its continued focus on innovations. The optimism, led by strong second-quarter fiscal 2024 performance and acquisitions, is expected to contribute further. However, geopolitical tensions and stiff competition are concerning.This Zacks Rank #2 (Buy) company’s shares have risen 3.1% in the past six months compared with 6.7% growth of the industry. The S&P 500 composite has risen 6.9% during the said time fram ...

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision tren ...

GE HealthCare Technologies Inc. GEHC shares are trading higher Wednesday. The stock was upgraded from Hold to Buy, while the price target was raised from $95 to $103 by Jefferies.But some traders and investors who hold shares may be selling them before they reach the $103 level. This is why it is our Stock of the Day.Successful traders don't guess. They let the market tell them what to do. They identify important price levels to determine where to place their orders.As you can see on the chart, the $94 leve ...